Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.53 |
| ▸ | STS | P08842 | 4/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436365 | 0.84 | GPR119 (0.58) | GPR119NAMPTKDM4EMAPTTHRB | |
| SCHEMBL21953943 | 0.83 | GPR119 (0.56) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL1613087 | 0.83 | GPR119 (0.56) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL21885666 | 0.82 | GPR119 (0.55) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL21885670 | 0.82 | GPR119 (0.55) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL21352374 | 0.82 | GPR119 (0.55) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL30436819 | 0.82 | GPR119 (0.55) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL2160640 | 0.82 | MEN1 (0.57) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL73493 | 0.82 | GPR119 (0.55) | GPR119STSNAMPTKDM4EMAPT | |
| SCHEMBL30534946 | 0.82 | GPR119 (0.55) | GPR119STSNAMPTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557112-B2 | Aromatic-ring-fused pyrimidine derivative | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1806347-A1 | AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249587-A1 | Aromatic-Ring-Fused Pyrimidine Derivative | GPR119, NOD1, IRS1 | GPR119 1/4885STS 2201/4885NAMPT 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.